Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies

In this episode, 2 experts discuss how immunotherapy has reshaped the treatment landscape of acute lymphoblastic leukemia (ALL), highlighting advances in bispecific antibodies, CAR T-cell therapies, and MRD-guided strategies in both frontline and relapsed/refractory settings. They also explore evolving decisions around toxicity, treatment sequencing, transplant, and the promise of more effective, less burdensome approaches that may further improve long-term outcomes.